Gene editing, synthetic biology, molecular diagnostics (ARK ARKG thesis)
Gene editing, synthetic biology, and molecular diagnostics megatrend.
| Symbol | Action | Vol | Stop Loss | Take Profit | Size | Links |
|---|---|---|---|---|---|---|
| ARKG | BUY | 44% | 40.0% below entry | 9.3% above entry | 1.1% | TVYH |
| A | BUY | 29% | 30.1% below entry | 6.0% above entry | 1.7% | TVYH |
| TMO | BUY | 28% | 29.8% below entry | 6.0% above entry | 1.7% | TVYH |
| TEM | BUY | 100% | 40.0% below entry | 15.0% above entry | 0.7% | TVYH |
| CRSP | BUY | 59% | 40.0% below entry | 12.4% above entry | 0.8% | TVYH |
| EDIT | BUY | 115% | 40.0% below entry | 15.0% above entry | 0.7% | TVYH |
| TXG | BUY | 73% | 40.0% below entry | 15.0% above entry | 0.7% | TVYH |
| BEAM | BUY | 74% | 40.0% below entry | 15.0% above entry | 0.7% | TVYH |
| ILMN | BUY | 46% | 40.0% below entry | 9.6% above entry | 1.0% | TVYH |
| TWST | BUY | 67% | 40.0% below entry | 14.0% above entry | 0.7% | TVYH |
| NTLA | BUY | 88% | 40.0% below entry | 15.0% above entry | 0.7% | TVYH |
This strategy has moderate long-term performance but HIGH volatility (genomics is binary). Consider allocating 3-5% of portfolio as a speculative diversifier. Do NOT make this a core holding. Simplest passive approach: Equal-weight CRSP, BEAM, ILMN, TMO, TWST. These five span gene editing leaders (CRSP, BEAM), the sequencing monopoly (ILMN), life science tools (TMO), and synthetic biology (TWST). Or simply buy ARKG for managed genomics exposure. Rebalance quarterly. Warning: Many genomics names (CRSP, BEAM, NTLA, EDIT) only IPO'd 2016-2020, so early windows have limited universe. Performance improves as more names become available. The 2020-2021 genomics bubble and subsequent crash (-70% drawdown) is the dominant risk.